rpl1101 Antibody

What is RPL11 and why is it an important research target?

RPL11 (Ribosomal Protein L11) is a component of the 60S large ribosomal subunit and plays critical roles in cellular function. It serves as an essential component of the ribosome, which is responsible for protein synthesis in cells. The small ribosomal subunit binds messenger RNAs (mRNAs) and translates the encoded message by selecting cognate aminoacyl-transfer RNA (tRNA) molecules, while the large subunit contains the ribosomal catalytic site called the peptidyl transferase center (PTC) . This catalytic center forms peptide bonds, polymerizing amino acids delivered by tRNAs into polypeptide chains.

RPL11 is particularly significant because it forms part of the 5S RNP/5S ribonucleoprotein particle that is essential for the formation of the large subunit and maturation of rRNAs . Beyond its structural role in ribosomes, RPL11 has regulatory functions, particularly in coupling ribosome biogenesis to p53/TP53 activation. When ribosome biogenesis is disrupted, RPL11 (as part of the 5S RNP) accumulates in the nucleoplasm and inhibits MDM2, leading to stabilization and activation of p53 . This mechanism represents an important cellular checkpoint linking ribosomal stress to cell cycle regulation and potentially cancer development.

What are the common applications for RPL11 antibodies in research?

RPL11 antibodies are versatile research tools applicable in multiple experimental techniques. Based on the available data, the primary applications include:

• Western Blotting (WB): RPL11 antibodies can detect the protein in cell and tissue lysates, typically showing bands at approximately 18-21 kDa . This application allows quantification of RPL11 expression levels across different experimental conditions or cell types.

• Immunoprecipitation (IP): Anti-RPL11 antibodies can successfully immunoprecipitate RPL11 from cell lysates, as demonstrated with HeLa cells . This technique is valuable for studying protein-protein interactions involving RPL11.

• Immunohistochemistry-Paraffin (IHC-P): RPL11 antibodies can detect the protein in fixed, paraffin-embedded tissues, revealing its localization in the cytosol and nucleus, as shown in HeLa xenograft models .

• Flow Cytometry (FC): Some RPL11 antibodies are suitable for flow cytometry applications, allowing analysis of RPL11 expression at the single-cell level .

These applications enable researchers to investigate RPL11's expression, localization, interactions, and potential role in disease mechanisms across various experimental systems.

What controls should be included when using RPL11 antibodies?

Proper controls are essential when using RPL11 antibodies to ensure experimental rigor and reproducibility. The inadequate characterization of antibodies has become a significant concern in biomedical research, with an estimated 50% of commercial antibodies failing to meet basic standards . To address this issue, researchers should implement the following controls:

• Positive Controls: Include samples known to express RPL11, such as HeLa cells, which have been successfully used in Western blot and immunoprecipitation applications with RPL11 antibodies . This verifies the antibody's ability to detect the target.

• Negative Controls:

  • Isotype Controls: Use a rabbit monoclonal IgG (or appropriate isotype for the specific antibody) instead of the primary RPL11 antibody, as demonstrated in immunoprecipitation experiments . This controls for non-specific binding of the antibody's constant region.

  • Samples with known low or no expression of RPL11, if available.

• Loading Controls: For Western blots, include housekeeping proteins (e.g., β-actin, GAPDH) to ensure equal loading across lanes.

• Blocking Peptide Controls: When available, use the specific peptide used to generate the antibody to competitively block binding, confirming signal specificity.

• Genetic Controls: If possible, use RPL11 knockdown or knockout samples to validate antibody specificity.

Implementing these controls helps distinguish specific from non-specific signals and enhances the reliability of results obtained with RPL11 antibodies, addressing the broader concerns about antibody reproducibility in research .

How should researchers optimize Western blot protocols for RPL11 detection?

Optimizing Western blot protocols for RPL11 detection requires careful consideration of several technical parameters:

• Sample Preparation:

  • Use appropriate lysis buffers that maintain protein integrity

  • Include protease inhibitors to prevent degradation

  • For cellular experiments, whole cell lysates from HeLa cells have been successfully used at 30 μg per lane

• Gel Selection and Running Conditions:

  • RPL11 is a relatively small protein (~20 kDa), so higher percentage gels (12-15% SDS-PAGE) provide better resolution in this molecular weight range

  • Expected band sizes: The primary band for RPL11 is typically observed at 18-21 kDa, though additional bands around 36 kDa may be detected in some samples

• Transfer Conditions:

  • Use PVDF or nitrocellulose membranes with pore sizes appropriate for small proteins

  • Consider semi-dry transfer or shorter transfer times for small proteins to prevent them from passing through the membrane

• Antibody Dilution and Incubation:

  • For primary RPL11 antibody: The recommended dilution is typically 1:1000 for Western blot applications

  • Overnight incubation at 4°C often yields better results than shorter incubations

• Detection Method:

  • Enhanced chemiluminescence (ECL) systems work well for RPL11 detection

  • Exposure time optimization: Start with 15 seconds exposure as a baseline, as this has been successful in previous experiments

• Troubleshooting Multiple Bands:

  • If multiple bands appear, consider performing blocking peptide competition to identify specific signal

  • Post-translational modifications or protein complexes may explain additional bands

By following these optimization guidelines, researchers can achieve reliable and reproducible detection of RPL11 in Western blot applications.

What are the key considerations for immunohistochemical detection of RPL11?

Immunohistochemical (IHC) detection of RPL11 requires attention to several critical parameters to ensure specific staining and accurate localization:

• Sample Preparation and Fixation:

  • Paraffin-embedded samples have been successfully used for RPL11 detection

  • Proper fixation is crucial: formalin fixation followed by paraffin embedding is commonly employed

  • Antigen retrieval methods may be necessary to expose epitopes masked during fixation

• Antibody Selection and Validation:

  • Choose antibodies validated for IHC applications, such as those demonstrated to work on HeLa xenografts

  • Verify the antibody's specificity through appropriate controls (see question 1.3)

• Staining Protocol Optimization:

  • Dilution: A dilution of 1:500 has been successful for RPL11 antibody in IHC applications on paraffin-embedded samples

  • Blocking: Use appropriate blocking solutions to minimize non-specific binding

  • Incubation time and temperature: Typically overnight at 4°C for primary antibody

• Expected Localization Patterns:

  • RPL11 is typically detected in both the cytosol and nucleus , consistent with its roles in ribosome biogenesis and p53 regulation

  • The staining pattern may change under conditions of ribosomal stress, with increased nuclear accumulation

• Signal Detection and Visualization:

  • Choose appropriate secondary antibodies and detection systems based on the primary antibody host species

  • Consider counterstaining nuclei (e.g., with hematoxylin) to provide context for RPL11 localization

• Image Acquisition and Analysis:

  • Use consistent exposure settings when comparing different samples

  • Consider quantitative analysis of staining intensity or subcellular distribution when appropriate

By addressing these considerations, researchers can achieve reliable IHC detection of RPL11, enabling studies of its expression levels and subcellular localization in normal and pathological tissues.

How can researchers ensure reproducibility when using RPL11 antibodies?

Ensuring reproducibility with RPL11 antibodies requires addressing the broader "antibody characterization crisis" affecting biomedical research . Here are comprehensive strategies to enhance reproducibility:

• Antibody Selection and Documentation:

  • Choose antibodies with documented validation data for your specific application (WB, IP, IHC, FC)

  • Record complete antibody information: vendor, catalog number, lot number, clone name (for monoclonals), host species, and antigen details

  • The exact epitope region (e.g., N-terminal region, amino acids 1-30 of RPL11) can affect performance in different applications

• Validation for Specific Applications:

  • Verify antibody performance in your experimental system, even if previously validated

  • For RPL11, validate with positive controls like HeLa cells and appropriate negative controls

  • Consider using multiple antibodies targeting different epitopes of RPL11 to confirm results

• Protocol Standardization:

  • Establish and document detailed protocols, including all reagents, dilutions, incubation times, and temperatures

  • For RPL11 antibodies, typical working dilutions are:

    • Western blot: 1:1000

    • Immunoprecipitation: 1:30 (2μg for 0.35mg lysate)

    • IHC-P: 1:500

    • Flow cytometry: 1:10-50

• Proper Storage and Handling:

  • Store antibodies according to manufacturer recommendations (typically at -20°C for long-term storage)

  • Avoid repeated freeze-thaw cycles by preparing small aliquots

  • Monitor antibody performance over time, as degradation can occur

• Data Reporting and Sharing:

  • Include complete methodological details in publications

  • Share raw, unprocessed images and complete blots

  • Report negative or contradictory results

• Quality Control Measures:

  • Periodically test antibody performance using standard samples

  • Implement consistent criteria for evaluating successful experiments

By implementing these practices, researchers can significantly improve the reproducibility of experiments using RPL11 antibodies, contributing to more reliable and translatable research findings in the field.

How can RPL11 antibodies be used to study the relationship between ribosome biogenesis and p53 regulation?

RPL11 antibodies are powerful tools for investigating the critical link between ribosome biogenesis and p53 regulation, a pathway implicated in cellular stress responses and cancer development. Advanced research approaches include:

• Studying Nucleoplasmic Accumulation of RPL11:

  • RPL11 antibodies can track the redistribution of RPL11 from nucleoli to nucleoplasm under ribosomal stress conditions

  • Immunofluorescence microscopy with RPL11 antibodies, combined with nucleolar markers, can visualize this translocation

  • This approach helps elucidate how disruptions in ribosome biogenesis trigger p53 activation

• Analyzing RPL11-MDM2 Interactions:

  • Co-immunoprecipitation using RPL11 antibodies can capture the RPL11-MDM2 complex that forms when ribosome biogenesis is perturbed

  • This complex is critical for inhibiting MDM2-mediated degradation of p53

  • Sequential immunoprecipitation (first with RPL11 antibody, then with MDM2 antibody) can isolate the specific complex

• Examining 5S RNP Complex Formation:

  • RPL11 is a component of the 5S RNP complex, essential for large ribosomal subunit formation and p53 regulation

  • RPL11 antibodies can be used in conjunction with antibodies against other 5S RNP components (5S rRNA, RPL5) to study complex assembly

  • Proximity ligation assays using RPL11 antibodies can visualize interactions within the complex in situ

• Quantifying RPL11 Levels During Ribosomal Stress:

  • Western blotting with RPL11 antibodies can measure changes in total RPL11 levels in response to ribosomal stressors

  • Subcellular fractionation followed by Western blotting can quantify the redistribution between cellular compartments

• Chromatin Immunoprecipitation (ChIP) Applications:

  • RPL11 has been implicated in transcriptional regulation

  • ChIP using RPL11 antibodies can identify genomic regions associated with RPL11 under normal and stress conditions

  • This approach can reveal how RPL11 contributes to gene expression changes during ribosomal stress

• Studying Post-translational Modifications:

  • RPL11 function is regulated by modifications like ubiquitination

  • Immunoprecipitation with RPL11 antibodies followed by Western blotting for ubiquitin can assess these modifications

  • Mass spectrometry analysis of immunoprecipitated RPL11 can identify novel modifications

These advanced applications of RPL11 antibodies enable detailed mechanistic studies of how ribosomal stress signals are transmitted to the p53 pathway, potentially revealing therapeutic targets for diseases involving dysregulated ribosome biogenesis.

How should researchers approach troubleshooting when RPL11 antibodies show unexpected results?

When RPL11 antibodies produce unexpected results, a systematic troubleshooting approach can help identify and resolve issues:

• Unexpected Banding Patterns in Western Blots:

  • Multiple bands: RPL11 has been observed at both 18 kDa and 36 kDa in some experiments . The 36 kDa band may represent dimerization or complexes with other proteins

  • Absence of expected band: Consider protein degradation, insufficient loading, or transfer issues specific to small proteins

  • Verification strategy: Use alternative antibodies targeting different RPL11 epitopes to confirm banding patterns

• Unexpected Subcellular Localization:

  • RPL11 should be detectable in both cytosol and nucleus , with distribution varying based on cellular conditions

  • If localization differs from expected: Verify fixation conditions, as overfixation may mask epitopes in certain cellular compartments

  • Verification approach: Use subcellular fractionation followed by Western blotting to confirm localization patterns observed in immunofluorescence or IHC

• Cross-reactivity Assessment:

  • If unexpected signals appear in negative control samples: Perform peptide competition assays to determine if the signal is specific to RPL11

  • For suspected cross-reactivity: Consider testing the antibody in RPL11-depleted samples (siRNA knockdown)

  • Sequence homology analysis: Check if the epitope region has similarity to other proteins that might explain cross-reactivity

• Species Reactivity Issues:

  • When using RPL11 antibodies across species: Although some RPL11 antibodies react with human, mouse, and rat samples , verify reactivity in your specific experimental system

  • For unexpected lack of reactivity: Compare the epitope sequence with the species-specific RPL11 sequence to identify potential differences

• Developing a Systematic Decision Tree:

  • Step 1: Verify antibody integrity (storage conditions, expiration)

  • Step 2: Test positive controls (e.g., HeLa cells for human samples)

  • Step 3: Optimize protocol parameters (antibody concentration, incubation conditions)

  • Step 4: Implement additional controls to distinguish between technical and biological explanations

  • Step 5: Consider alternative antibodies or detection methods if issues persist

• Documenting Troubleshooting Process:

  • Maintain detailed records of all troubleshooting steps

  • Document both successful and unsuccessful approaches to inform future experiments

By following this structured approach, researchers can effectively troubleshoot unexpected results with RPL11 antibodies, distinguishing between technical artifacts and potentially novel biological insights.

What considerations are important when using RPL11 antibodies to study cancer and disease mechanisms?

RPL11 plays critical roles in ribosome biogenesis and p53 regulation pathways that are frequently dysregulated in cancer. When using RPL11 antibodies to study disease mechanisms, researchers should consider:

• Context-Specific Expression Patterns:

  • RPL11 expression and localization may vary significantly across cancer types and stages

  • Comprehensive analysis should include:

    • Multiple cancer cell lines or patient samples

    • Comparison with appropriate normal tissue controls

    • Correlation with clinical parameters when using patient samples

• Integration with p53 Pathway Analysis:

  • RPL11's role in p53 regulation makes it important to assess p53 status in parallel

  • Consider analyzing:

    • p53 expression and activation status

    • MDM2 levels and interaction with RPL11

    • Downstream p53 target genes

  • This integrated approach provides mechanistic context for RPL11 observations

• Ribosomal Stress Responses:

  • Many cancer treatments induce ribosomal stress

  • RPL11 antibodies can monitor how cancer cells respond to:

    • Chemotherapeutics that disrupt nucleolar function

    • Targeted therapies affecting ribosome biogenesis

    • Radiation treatment

• Correlation with Other Ribosomal Proteins:

  • RPL11 functions within the 5S RNP complex alongside other components

  • Consider parallel analysis of RPL5 and 5S rRNA

  • Disruption of stoichiometry between these components may have pathological implications

• Technical Considerations for Clinical Samples:

  • Tissue fixation and processing can affect epitope accessibility

  • Validation on FFPE tissues is critical before analyzing clinical samples

  • Quantitative approaches (like digital pathology) may reveal subtle but important differences in RPL11 patterns

• Translational Potential:

  • Consider whether RPL11 detection might serve as a biomarker

  • Similar to the approach used for ITPRIPL1 in non-small cell lung cancer , evaluate:

    • Sensitivity and specificity in distinguishing disease from normal tissue

    • Correlation with immune cell infiltration or other tumor microenvironment features

    • Potential predictive value for treatment response

• Controls Specific to Disease Research:

  • Include multiple control tissues representing different states:

    • Normal adjacent tissue

    • Pre-malignant tissue (when available)

    • Different grades/stages of disease

By addressing these considerations, researchers can maximize the value of RPL11 antibodies in disease-focused studies, potentially revealing new insights into disease mechanisms and therapeutic opportunities.

How can ultra-sensitive detection methods be applied to RPL11 research?

Recent advances in ultra-sensitive detection technologies, similar to those developed for IL-11 target engagement assays , can be applied to RPL11 research to enable detection of previously unquantifiable levels of the protein and reveal new biological insights:

• Adapting Platform Technologies for RPL11 Detection:

  • Several platforms could be optimized for ultra-sensitive RPL11 detection:

    • Simoa HD-1 and Simoa Planar Array (SP-X) technologies, which have achieved detection limits as low as 0.006 pg/mL for other proteins

    • Meso Scale Discovery (MSD) electrochemiluminescence platform

    • Single-molecule counting technologies

  • These approaches could detect RPL11 in biological fluids where traditional methods fail

• Development of "Free" and "Total" RPL11 Assays:

  • Similar to IL-11 assays , distinct epitope-specific antibodies can be used to distinguish:

    • "Free" RPL11 not bound in complexes

    • "Total" RPL11 (both free and complex-bound forms)

  • This distinction is particularly relevant for studying RPL11's dual roles in ribosomes and p53 regulation

• Application to Minimal Sample Volumes:

  • Ultra-sensitive methods enable analysis of limited samples such as:

    • Rare patient specimens

    • Microdissected tissue regions

    • Extracellular vesicles

    • Circulating tumor cells

• Detection of RPL11 in Extracellular Environment:

  • Ultra-sensitive assays could determine if RPL11 is present in:

    • Plasma or serum

    • Cerebrospinal fluid

    • Tumor microenvironment

  • This could reveal previously unknown extracellular functions or biomarker potential

• Quantifying Dynamic Changes in RPL11:

  • Ultra-sensitive methods can detect subtle changes in RPL11 levels during:

    • Cell cycle progression

    • Early stress responses

    • Initial stages of disease development

  • These changes might be below the detection threshold of conventional methods

• Multiplex Analysis with Related Proteins:

  • Development of multiplex panels including RPL11 alongside:

    • Other 5S RNP components

    • p53 pathway proteins

    • Additional ribosomal proteins

  • This provides a systems-level view of ribosome biogenesis and stress responses

By implementing these ultra-sensitive approaches, researchers can expand RPL11 studies beyond current limitations, potentially revealing new mechanisms of action and disease associations at previously undetectable levels.

What are the latest developments in using RPL11 antibodies for cancer diagnostics and therapeutic monitoring?

While RPL11 itself has not been extensively explored as a cancer biomarker, insights from similar research with other proteins suggest promising avenues for RPL11 antibody applications in cancer:

• Potential Diagnostic Applications:

  • The ITPRIPL1 antibody study for non-small cell lung cancer (NSCLC) provides a model for RPL11 exploration :

    • High immunohistochemical positivity in tumor samples with negative staining in normal tissues suggests similar approaches could be developed for RPL11

    • Homogeneous staining patterns could help delineate precise tumor boundaries

    • Correlation with immune cell infiltration might be relevant for RPL11 as well, given its role in stress pathways

• Therapeutic Target Engagement Monitoring:

  • Ultra-sensitive antibody-based assays could monitor the effects of therapies targeting:

    • Ribosome biogenesis

    • p53 pathway activation

    • Nucleolar stress responses

  • These assays could provide pharmacodynamic biomarkers for drug development

• Liquid Biopsy Development:

  • Ultra-sensitive detection methods might enable:

    • Detection of RPL11 or RPL11 complexes in circulation

    • Monitoring of extracellular vesicle-associated RPL11

    • Analysis of post-translational modifications on circulating RPL11

• Companion Diagnostic Potential:

  • RPL11 status might predict response to therapies that:

    • Induce nucleolar stress

    • Reactivate wild-type p53

    • Target ribosome biogenesis

• Methodological Considerations:

  • Standardization of RPL11 detection methods is essential for clinical applications

  • Rigorous antibody validation following guidelines addressing the "antibody characterization crisis" is particularly crucial for diagnostic development

  • Multiple antibody clones recognizing different epitopes should be evaluated for optimal performance

• Integration with Multi-Biomarker Panels:

  • RPL11 detection might be most valuable when combined with:

    • Other ribosomal stress markers

    • p53 pathway components

    • Established cancer biomarkers

• Emerging Technologies:

  • Spatial transcriptomics combined with RPL11 antibody-based imaging could provide insight into tumor heterogeneity

  • Mass cytometry (CyTOF) with RPL11 antibodies could enable single-cell analysis of ribosomal stress responses in tumor cells

While these applications remain largely theoretical for RPL11, the successful development of antibody-based assays for other cancer biomarkers suggests feasible translational pathways. The development of such applications would require extensive validation studies to establish clinical utility beyond current research applications.

What best practices should researchers follow when selecting and validating RPL11 antibodies?

Based on the current understanding of antibody validation challenges and RPL11-specific considerations, researchers should implement these best practices:

• Comprehensive Selection Criteria:

  • Evaluate multiple antibody characteristics:

    • Target epitope location (N-terminal, C-terminal, or internal regions)

    • Host species and antibody format (monoclonal vs. polyclonal)

    • Validated applications (WB, IP, IHC, FC) with supporting data

    • Lot-to-lot consistency information

  • Consider the specific experimental question, as different epitopes may perform differently depending on RPL11's conformation or interactions

• Multi-method Validation Approach:

  • Implement multiple validation strategies to address the "antibody characterization crisis" :

    • Genetic approaches: Testing in RPL11 knockdown/knockout models

    • Orthogonal methods: Comparing results from multiple detection technologies

    • Independent antibody verification: Using antibodies targeting different epitopes

    • Expression pattern verification: Confirming expected tissue or cellular distribution

• Application-Specific Optimization:

  • For Western blotting: Optimize for the small size of RPL11 (~20 kDa) with appropriate gel percentage and transfer conditions

  • For immunoprecipitation: Verify efficiency with Western blot analysis of input, bound, and unbound fractions

  • For immunohistochemistry: Validate fixation and antigen retrieval conditions specific to RPL11

  • For flow cytometry: Optimize permeabilization to ensure access to intracellular RPL11

• Documentation and Reporting Standards:

  • Maintain comprehensive records including:

    • Complete antibody information (vendor, catalog number, lot number, clone)

    • Validation data for specific applications

    • Detailed protocols with all critical parameters

  • Report negative or inconsistent results to vendors and the research community

• Addressing Reproducibility Challenges:

  • Implement controls for every experiment:

    • Positive controls (e.g., HeLa cells for human RPL11)

    • Negative controls (isotype controls, samples lacking RPL11)

    • Loading/procedural controls

  • Periodically revalidate antibodies, especially with new lots

• Creating a Decision Matrix for RPL11 Antibody Selection:

  Research Question	Recommended Antibody Type	Critical Validation
  Expression levels	Monoclonal with proven specificity	Western blot with knockdown controls
  Protein interactions	Antibodies with epitopes outside interaction domains	Co-IP with reciprocal pulldowns
  Subcellular localization	Validated for IHC/IF with consistent localization pattern	Fractionation controls
  Post-translational modifications	Epitopes away from modification sites	Modification-specific controls

By adhering to these best practices, researchers can significantly improve the reliability and reproducibility of their studies using RPL11 antibodies, contributing to higher-quality research in ribosome biology and related fields.

How can researchers contribute to improving the antibody characterization landscape?

Individual researchers can play a significant role in addressing the "antibody characterization crisis" while advancing RPL11 research through these proactive approaches:

• Comprehensive Validation and Reporting:

  • Conduct and publish thorough validation studies for RPL11 antibodies

  • Include detailed methodology sections in publications with complete antibody information

  • Report negative results and validation challenges to improve the knowledge base

• Data Sharing and Community Resources:

  • Contribute validation data to antibody validation repositories

  • Share protocols and troubleshooting tips through platforms like protocols.io

  • Participate in community efforts to standardize antibody validation criteria

• Implementation of the "Five Pillars" Validation Approach:

  • Genetic strategies: Test antibodies in RPL11 knockdown/knockout models

  • Orthogonal methods: Compare antibody-based results with mass spectrometry

  • Independent antibody verification: Use multiple antibodies against different RPL11 epitopes

  • Expression patterns: Verify consistency with known RPL11 biology

  • Tagged proteins: Compare detection of tagged RPL11 with antibody detection

• Collaboration with Antibody Vendors:

  • Provide feedback on antibody performance in specific applications

  • Suggest improvements to validation data provided with commercial antibodies

  • Participate in beta testing of new RPL11 antibodies

• Adoption of Recombinant Antibody Technologies:

  • Consider using recombinant monoclonal antibodies like EPR28901-64 for improved consistency

  • Support efforts to develop and characterize recombinant antibodies for research

• Education and Training Initiatives:

  • Develop training materials for proper antibody validation

  • Include rigorous antibody validation methods in graduate and postdoctoral training

  • Promote awareness of the importance of antibody characterization

• Supporting Reproducibility Through Methodological Transparency:

  • Document both successful and failed experimental conditions

  • Include detailed troubleshooting guides in supplementary materials

  • Adopt the RRID (Research Resource Identifier) system for antibody citation

By engaging in these activities, researchers studying RPL11 can contribute to solving the broader antibody reproducibility challenge while advancing their specific research area. This collective effort will ultimately enhance the quality and reliability of antibody-based research across biomedical sciences.

What are the recommended resources for further information on RPL11 antibodies and their applications?

Researchers seeking to deepen their knowledge of RPL11 antibodies and their applications should consult these specialized resources:

• Antibody Validation Resources:

  • The Antibody Validation Initiative provides guidelines for comprehensive antibody validation

  • The International Working Group for Antibody Validation (IWGAV) guidelines offer standardized approaches

  • The Human Protein Atlas contains validation data for antibodies against human proteins, including RPL11

• RPL11 Protein Information Databases:

  • UniProt entry for RPL11 (P62913) provides comprehensive protein information and functional annotations

  • The Protein Data Bank (PDB) contains structural information on RPL11 within ribosomal complexes

  • The Human Proteome Project resources include mass spectrometry data for RPL11

• Technical Protocols and Optimization Guides:

  • Manufacturer protocols for specific RPL11 antibodies:

    • Abcam (ab318976)

    • Novus/Bio-Techne (NBP2-20210)

    • Abcepta (AP12353a)

  • Application-specific technical notes on optimizing conditions for small ribosomal proteins

• Research Literature on RPL11 Functions:

  • Key publications on RPL11's role in ribosome biogenesis (PubMed:19191325, PubMed:32669547)

  • Studies on RPL11's function in the 5S RNP (PubMed:12962325, PubMed:19061985, PubMed:24120868)

  • Research on RPL11's role in p53 regulation (PubMed:24120868)

• Comparative Resources for Antibody Technologies:

  • Reviews on recombinant versus traditional antibody technologies

  • Benchmarking studies comparing antibody performance across vendors

  • Meta-analyses of antibody reproducibility in biomedical research

• Methodological Resources for Advanced Applications:

  • Ultra-sensitive detection technologies adaptable to RPL11 research

  • Protocols for studying protein-protein interactions involving ribosomal proteins

  • Guides for subcellular fractionation to study compartmentalization of ribosomal proteins